IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma
Authors Liu Y, Zhao JJ, Zhou ZQ, Pan QZ, Zhu Q, Tang Y, Xia JC, Weng DS
Received 7 January 2019
Accepted for publication 11 June 2019
Published 18 July 2019 Volume 2019:11 Pages 6691—6702
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 3
Editor who approved publication: Professor Lu-Zhe Sun
Yuan Liu,1,2,* Jing-Jing Zhao,1,2,* Zi-Qi Zhou,1,2 Qiu-Zhong Pan,1,2 Qian Zhu,1,2 Yan Tang,1,2 Jian-Chuan Xia,1,2 De-Sheng Weng1,2
1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China; 2Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China
*These authors contributed equally to this work
Introduction: IL-37 is a cytokine of IL-1 family that plays an important role in innate immunity and inflammation, and has been studied as a tumor suppressor in many cancers. However, it remains unclear whether IL-37 plays a regulatory role in tumor-infiltrating dendritic cells (DCs) in hepatocellular carcinoma (HCC).
Materials and methods: We evaluated the relationship between IL-37 expression and tumor infiltration by DCs in 155 HCC samples through immunohistochemical analysis and Kaplan–Meier survival analysis. The effects of IL-37 on the anti-tumor activity of DCs were investigated by ELISA, flow cytometry, real-time quantitative PCR, cytotoxicity assays and tumorigenicity assays.
Results: The expression level of IL-37 in HCC samples was positively correlated with the degree of CD1a+ DCs infiltration. The survival rates of patients with both a high expression of IL-37 and a high infiltration by CD1a+ DCs were significantly higher than those of patients with a low expression of IL-37 and a low infiltration by CD1a+ DCs. In vitro chemotaxis analysis indicated that HCC cells overexpressing IL-37 recruited more DCs by secreting higher levels of specific chemokines (eg, CCL3 and CCL20). In addition, IL-37 indirectly up-regulated the expression of major histocompatibility class II molecules, CD86 and CD40 on DCs by acting on tumor cells; IL-37 also indirectly enhanced the anti-tumor effect of T lymphocytes by stimulating DCs to secrete cytokines such as IL-2, IL-12, IL-12p70, interferon-α (IFN-α) and IFN-γ. Finally, overexpression IL-37 in HCC cells significantly delayed tumor growth and increased recruitment of CD11c+ DCs to tumor tissues was also revealed in vivo mouse model.
Conclusion: DCs play an important role in IL-37 mediated anti-tumor immune responses in HCC, which may contribute to the development of novel cancer immunotherapeutic strategies.
Keywords: IL-37, dendritic cells, antitumor immunity, hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and is a leading cause of cancer-related mortality.1 Although the effectiveness of early diagnosis and treatment has been significantly improved by the implementation of surveillance programs and individualized treatment in recent years, the HCC incidence of morbidity and mortality is still on the rise.2 The current effective treatments are limited to the following methods: surgical resection, ablation, and transplantation.3 Furthermore, recurrence after cure, drug resistance, and HCC heterogeneity are all difficult problems that are yet to be solved.4,5 Therefore, exploring new treatment strategies and improving current treatment methods are both urgently needed to solve this global public health problem.
Recent work has revealed the mechanisms underlying tumor immunosuppression and immune escape. Dendritic cells (DCs), as initiators of the naive T cell response, are key regulators of immune tolerance and activation, are essential for inducing and maintaining anti-tumor immune responses. Moreover, DCs are considered to be the most effective professional antigen-presenting cells (APCs). In the context of tumor immune escape, cancer vaccination, and the anti-tumor immune response, DCs have been extensively studied.6,7 Decreased expression levels of major histocompatibility class I (MHC I) molecules and co-stimulatory molecules present on the DCs surface are significant contributors to tumor immune escape.8 DCs have also recently been reported to play important roles in both the development and immunosuppression of HCC.9 A subset of CD14+ CTLA-4+ regulatory dendritic cells (CD14+ DCs) have been identified that inhibit the anti-tumor immune response through the CTLA-4-dependent production of IL-10 and indoleamine 2,3-dioxygenase in HCC.10 Patients with HCC also exhibit diminished functioning of DCs in their peripheral blood and fewer mature and activated DCs in their liver tissue.11 Importantly, a functional defect in DCs leads to impaired stimulation of allogeneic T cells.11,12
IL-37, a member of the IL-1 family, is essential to the inhibition of innate immunity and inflammation and plays a role in the inhibition of cytokines, chemokines, and neutrophil infiltration.13 IL-37 has also been reported to have anti-tumor effects in cancers such as colon cancer, cervical cancer, and prostate cancer.14–16 The mechanism of tumor suppression by IL-37 is dependent on cancer type. For instance, IL-37 inhibits the STAT4 signaling pathway in cervical and renal cancer.17 The anti-tumor effect of IL-37 in breast cancer is CD4+ T cell-dependent.18 We previously found that the IL-37 expression level is lower in tumor tissue, compared with adjacent tissue and negatively correlates with tumor size in HCC. However, age, gender, histological differentiation, liver cirrhosis, HBV, serum AFP, recurrence and distant metastasis had no correlates with IL-37 expression. Patients with high expression level of IL-37 in tumor tissue have better prognosis, including overall survival (OS) and disease-free survival (DFS), and the anti-tumor effect of IL-37 in HCC reflects CD57+ natural killer (NK) cell dependence.19 However, the role of IL-37 in modulating other tumor-infiltrating immune cells in the tumor microenvironment of HCC remains unclear. Therefore, we analyzed the relationship between IL-37 expression and DCs infiltration in patients with HCC and their effect on prognosis, then investigated the specific effects of IL-37 on the function of DCs.
Materials and methods
Patients and tissue specimens
Paraffin-embedded tissues and clinical data were obtained from the Sun Yat-sen University Cancer Center. The total number of patients included in this study was 155. Written informed consent for each patient was obtained, which was conducted in accordance with the Declaration of Helsinki. All of the patients had not received any treatment before surgery and were followed up for >5 years. The period of time from surgery to recurrence or the last follow-up without recurrence was defined as DFS. The period of time from surgery to death or the last known follow-up was defined as OS. This study was approved by the Ethics Committee of the Sun Yat-sen University Cancer Center.
Paraffin-embedded tissue sections (2 μm) collected from HCC patients and animal experiments were used for immunohistochemistry. All sections were heated in the oven for 1 hr at 65°C and rehydrated using graded ethanol. In order to adequately expose antigen, slides were boiled in EDTA (1 mmol/L, pH 8.0) for 15 mins in a microwave oven and naturally cooled to room temperature. To block endogenous peroxidase activity, the sections were washed for twice with PBS soaked in 3% hydrogen peroxide for 15 mins at room temperature. Then, all slides from HCC patients were incubated with primary monoclonal antibodies: mouse anti-human IL-37 (1:1,000 dilution; Abcam, Cambridge, UK), mouse anti-human CD1a (1:100 dilution; Zhongshan Golden Bridge Biotech Co., Ltd, Beijing, China). All slides from animal experiments were incubated with primary monoclonal antibodies: rabbit anti-mouse IL-37 (1:1,000 dilution; Tianjun, Guangzhou, China), rabbit anti-mouse CD11c (1:2,000 dilution; Tianjun), rabbit anti-mouse CD4 (1:1,000 dilution; Tianjun) and rabbit anti-mouse CD8 (1:1,000 dilution; Tianjun) at 4°C overnight. All slides were washed with PBS three times again and incubated with horseradish peroxidase-conjugated secondary antibody (Envision Detection Kit, Dako, Copenhagen, Denmark) for 30 mins at room temperature, then washed with PBS three times. Finally, sections were treated with 3,3′-diaminobenzidine tetrahydrochloride and observed with a microscope, counterstained with 20% hematoxylin, dehydrated, cleared, and evaluated.
Total IL-37 and CD1a immunostaining was determined by scoring the percentage of positively stained tumor cells and the intensity of staining. Percent positive scores were determined to be “0” (<5%, negative), “1” (5–25%, sporadic), “2” (25–50%, focal), or “3” (>50%, diffuse). Staining intensity scores were determined to be “0” (negative), “1” (faint staining), “2” (moderate staining), or “3” (strongly staining). The result of multiplying percent positive score and staining intensity score was used to calculate the total IL-37 and CD1a immunostaining score and ranged from 0 to 9. The expression level of IL-37 protein and the infiltration by CD1a+ DCs was classified as high (final immunostaining score fell within the range of 4–9) or low (final immunostaining score fell within the range of 0–3). The densities of CD1a, CD11c, CD4 and CD8 positively stained cells were manually counted under high-power (400×) magnification in five randomly selected fields and then averaged (cells/HPF).
Cell lines and culture
The human HCC cell line Hep3B and mouse HCC cell line Hepa 1–6 (syngeneic to C57BL/6 mice) were obtained from the American Type Culture Collection (Manassas, VA, USA). Hep3B cells were cultured in DMEM medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% heat-inactivated FBS (Thermo Fisher Scientific) and 1% penicillin–streptomycin. Hepa 1–6 cells were cultured in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% heat-inactivated FBS and 1% penicillin–streptomycin. All cells were incubated at 37°C in a humidified chamber containing 5% CO2.
Overexpression of IL-37 in HCC cells
Hep3B and Hepa 1–6 cells (8×105/2 mL DMEM medium or RPMI 1640 medium per well) were plated in six-well culture dishes and incubated for 24 hrs. Then, in the presence of 5 μg/mL polybrene (Sigma-Aldrich, St. Louis, MO, USA), the cells were infected with the lentiviruses (LV-NC and LV-IL37) at a multiplicity of infection of 40. Puromycin (5 μg/mL) was used to select stable cell lines (Hep3B/LV-NC and Hep3B/LV-IL37; Hepa 1–6/LV-NC and Hepa 1–6/LV-IL37), and the successful induction was confirmed by using Western blotting and ELISA.
Immune cell isolation and culture
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats (Guangzhou Blood Center, Guangzhou, China) by Ficoll-Hypaque density gradient centrifugation. PBMCs were then seeded (1×108 cells) into 75 cm2 culture bottles for 2 hrs. Non-adherent cells were collected and cultured in Quanta-007 lymphocyte medium (PAA, Freiburg, Germany) supplemented with IL-2 (20U/ml) for T cell isolation. Dynabeads magnetic beads (Life Technologies, Shanghai, China) were used to isolate CD3+ T lymphocytes by negative selection according to the manufacturer’s instructions. Culture bottles were washed twice with PBS, unwashed cells were treated with 400 U/mL IL-4 (Thermo Fisher Scientific) and 1,000 U/mL GM-CSF (Thermo Fisher Scientific) for 5 days. Then, suspended cells were collected and treated with 10 μg/mL OK-432 (Shandong Lukang Pharmaceutical Co., Ltd, Jining, China) for 24 hrs to generate mature DCs (mDCs).
DCs loaded with antigen of Hep3B cells
The cryopreserved Hep3B cells in liquid nitrogen tank were placed in warm water (37°C). After dissolved, the cells were put into liquid nitrogen tank again for rapid freezing, repeated four times, and the supernatant was retained after centrifugation. Then, cell lysates of Hep3B cells were obtained. The mDCs were cultured in medium containing Hep3B cell lysates for 24 hrs.
Chemotaxis assays in vitro
Hep3B/LV-IL37 and Hep3B/LV-NC cells (2×105/2ml DMEM per well) were plated in six-well culture dishes and incubated for 72 hrs. Then, culture supernatants were collected and stored at −80°C as aliquots. Polycarbonate filters with a 5-μm pore size in 24-well transwell chambers (Corning Inc, Corning, NY, USA) were used to perform chemotaxis assays. Purified mDCs (5×106 cells) suspended in 100 μL of complete medium were placed in the upper chamber, and 600 μL of one of the following was added to the lower chamber: supernatant from a Hep3B/LV-IL37 cell culture, supernatant from a Hep3B/LV-NC cell culture, DMEM containing recombinant IL-37 (the content of IL-37 in DMEM was similar to that in the supernatant of Hep3B/LV-IL37 cells), or DMEM alone. Each experiment was performed in triplicate. Cells were incubated for 4 hrs at 37°C. Then, cells migrated to the bottom chamber were collected, suspended and counted.
Real-time quantitative PCR (qPCR)
The TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from the Hep3B/LV-IL37 cells, Hep3B/LV-NC cells, and DCs (cultured in DMEM with or without recombinant IL-37, Hep3B/LV-NC cell culture supernatant, Hep3B/LV-IL37 cell culture supernatant). The SYBR Green Master Mix (Invitrogen) was used to evaluate the expression levels of mRNAs encoding CCL chemokines, CXC chemokines, and GAPDH in an ABI Prism 7900HT Sequence Detection System (Life Technologies, Carlsbad, CA, USA). The specific primers used are presented in Table S1. Data were calculated and analyzed using the comparative threshold cycle (2−∆∆Ct) method.
Flow cytometry analysis
Mature DCs (mDCs) loaded with antigen of Hep3B cells (Hep3B cell lysates) were cultured for 24 hrs in DMEM alone, with recombinant IL-37, with Hep3B/LV-NC cell culture supernatant, or with Hep3B/LV-IL37 cell culture supernatant, two duplicate wells. Half of the mDCs were used to detect the expression level of CD80, CD86, CD40, MHC Class I and MHC Class II. Half of the mDCs were incubated with purified CD3+T cells to detect interferon-γ (IFN-γ) expression of cytotoxic T lymphocytes (CTLs) and the proportion of IFN-γ+CD8+T cells. The antibodies applied in the assay are as follows: FITC-conjugated antibodies: anti-MHC Class I, anti-MHC Class II, anti-CD80, anti-CD86, anti-CD40 and anti-CD8; APC-conjugated anti-IFN-γ (all from BD Biosciences, Franklin Lakes, NJ, USA). The data analysis of CD80, CD86, CD40, MHC Class I, MHC Class II and CD8 was performed using a Cytomics FC 500 Flow Cytometer (Beckman Coulter, Brea, CA, USA). The data analysis of IFN-γ was performed using the CXP Analysis software (Beckman Coulter).
Lymphocyte proliferation assay
The CellTrace CFSE Cell Proliferation Kit (Molecular Probes, Shanghai, China) was used to determine the number of active T cells according to the manufacturer’s protocol.
Generation of CTLs and cytotoxicity assays in vitro
Mature DCs (mDCs), loaded with antigen of Hep3B cells (Hep3B cell lysates), were cultured for 24 hrs in DMEM alone, with recombinant IL-37, with Hep3B/LV-NC cell culture supernatant, or with Hep3B/LV-IL37 cell culture supernatant; the cells were then collected, washed extensively, and incubated with purified CD3+ T cells for 7 days to generate CTLs. Then, CTLs were co-cultured with Hep3B cells at a ratio of 1:1, 3:1, or 10:1 for 12 hrs. The cytotoxicity of CTLs was assessed using a CytoTox 96 Lactate Dehydrogenase Assay Kit (Promega, Madison, WI, USA) according to the manufacturer’s protocol.
Mature DCs (mDCs), loaded with antigen of Hep3B cells (Hep3B cell lysates), were cultured in DMEM alone, with recombinant IL-37, with Hep3B/LV-NC cell culture supernatant, or with Hep3B/LV-IL37 cell culture supernatant. A commercially available ELISA Kit (4A Biotech Co, Ltd, Beijing, China) was used to examine the level of CXCL10, IL-2, IL-6, IL-10, IL-12, IL-12p70, TNF-α, IFN-α and IFN-γ secreted into the supernatants by mDCs according to the manufacturer’s protocol. The level of IL-37 secreted by Hep3B/LV-IL37 cells, Hep3B/LV-NC cells, Hepa 1–6/LV-IL37 cells or Hepa 1–6/LV-NC cells was similarly examined.
HCC proliferation assays
Hepa 1–6/LV-IL37 cells and Hepa 1–6/LV-NC cells were counted and seeded in 96-well plates at 1,000 cells/200 μL per well. The MTS cell proliferation kit (Promega) was used to measure the proliferation rates of Hepa 1–6/LV-IL37 cells and Hepa 1–6/LV-NC cells according to the manufacturer’s instructions.
Tumorigenicity assays in C57BL/6 mice
Female C57BL/6 mice (5 weeks old) were obtained from the Medical Experimental Animal Center of Guangdong and maintained in a specific-pathogen-free environment in the animal experimental center of Sun Yat-sen University. All the mice were randomly divided into two groups, six mice in each group. Group 1: mice were injected with Hepa 1–6/LV-IL37 cells; Group 2: mice were injected with Hepa 1–6/LV-NC cells (2×106 tumor cells suspended in 100 μL of PBS). The length (L) and width (W) of each tumor were measured every 3 days. The tumor volumes were calculated according to the following formula: (L × W2)/2. Eighteen days after tumor cells were inoculated, all mice were sacrificed to harvest, photographed, weighed the tumors. Then, tumors were fixed in formalin overnight, dehydrated, and embedded in paraffin. Tumors were sectioned at a thickness of 2 μm to determine IL-37 expression, CD11c+ DCs, CD4+T cells and CD8+T cells infiltration by immunohistochemical analysis. CD11c+ DCs, CD4+T cells and CD8+T cells were calculated from five fields per section as the mean number of positively stained cells per random high-power microscopic field (HPF, 400× magnification). All procedures of animal experiments in this study were performed according to the guidelines of the laboratory animal ethics committee of Sun Yat-sen University.
All statistical analyses were conducted using SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) or the GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). Unpaired t-test or the Mann–Whitney U test was used to compare the differences between two experimental groups. One-way ANOVA was used to compare multiple experimental groups. OS and DFS curves were constructed according to the Kaplan–Meier estimate and were analyzed through the log-rank test. The results are represented as the mean ± SD. A two-tailed P-value ≤0.05 was considered statistically significant.
The degree of CD1a+ DCs infiltration is correlated with IL-37 expression in the tumor tissue of HCC
To explore whether the expression of IL-37 was associated with the infiltration of CD1a+ DCs in tumor microenvironment of HCC. We examined the infiltration of CD1a+ DCs and IL-37 expression in 155 specimens of HCC. Indeed, IL-37 expression was positively correlated with the degree of CD1a+ DCs infiltration (Figure 1A). Comparative analysis further confirmed this trend (P=0.038; Figure 1B). Based on the expression levels of IL-37 and CD1a+ DCs infiltration levels in all 155 patients with HCC, the IL-37highDChigh patients had the best prognosis (Figure 1C and D).
IL-37 indirectly promotes the migration of DCs by triggering chemokine release from HCC cells
Then, we explored whether IL-37 has a direct effect on the migration of DCs and its potential mechanism. The lentiviral vector LV-IL37 carrying the gene encoding and control empty vector LV-NC was transduced into the human HCC cell line Hep3B, respectively. Western blotting and ELISA were performed to determine the transfection efficiencies (Figure 2A and B). Then, chemotaxis assay was used to test the ability of IL-37-overexpressing HCC cells to recruit DCs in vitro. The result showed that a significantly higher number of DCs recruited by the supernatant of Hep3B/LV-IL37 cells than the supernatant of Hep3B/LV-NC cells, DMEM with recombinant IL-37 (the content of IL-37 in DMEM was similar to that in the supernatant of Hep3B/LV-IL37 cells), or DMEM alone (Figure 2C). However, there were no obvious differences in recruitment by the supernatant of Hep3B/LV-NC cells, DMEM with recombinant IL-37, and DMEM alone. It suggested that IL-37 has no direct effect on the migration of DCs. CCL chemokines were considered to be inducers during the migration of DCs into tumor tissues.20,21 To test whether IL-37 had an effect on the production and secretion of CCL chemokines from HCC cells. Therefore, we performed real-time-qPCR to determine the CCL chemokine profiles of Hep3B/LV-NC cells and Hep3B/LV-IL37 cells. Expression levels of mRNAs encoding the chemokines CCL3 and CCL20 were significantly up-regulated in Hep3B/LV-IL37 cells compared to Hep3B/LV-NC cells (Figure 2D). These results suggested that IL-37 may stimulate chemokine release by tumor cells to recruit DCs into tumor tissue indirectly.
IL-37 indirectly enhances the ability of DCs to induce anti-tumor immune response
It is well known that the expression of co-stimulatory molecules and MHC like molecules is essential for DCs to induce anti-tumor immune response. Previous studies have demonstrated that decreased expression of co-stimulatory molecules and MHC class molecules present on the surface of DCs can contribute significantly to tumor immune escape.8 We examined the effect of IL-37 on the expression of co-stimulatory molecules and MHC molecules on the DC surface. Flow cytometry was used to detect the expression of CD80, CD86, CD40, MHC class I and MHC class II on the surface of DCs. The proportion of CD86, CD40 and MHC class II on the surface of DCs treated with the supernatant of Hep3B/LV-IL37 cells was significantly higher than on the surface of DCs treated with the supernatant of Hep3B/LV-NC cells, DMEM with recombinant IL-37, or DMEM alone. Interestingly, there was no significant difference in the proportion of CD86 and MHC class II on the surface of DCs treated with the supernatant of Hep3B/LV-NC, DMEM with recombinant IL-37, or DMEM alone. In addition, the proportion of CD40 on the surface of DCs treated with the supernatant of Hep3B/LV-NC or DMEM with recombinant IL-37 were decreased (Figure 3A and B).
IL-12p70 and IFN-γ, as Th1-type cytokines, enhance the phagocytosis and cytotoxicity of effector cells, including CTLs, NK cells, and macrophages, to promote an anti-tumor immune response.22,23 IL-2, IL-12, and CXCL10 can induce and enhance the CTL anti-tumor immune response.22–26 Increased expression and secretion of IL-1, IL-6 and TNF-α were also essential for the induction of beneficial immune responses by mature DCs. In addition, IFN-α secreted by DC cells played an important role in stimulating its activation and inducing anti-tumor immune response.27 However, IL-10 secreted by DC cells inhibited adaptive immune response.28 We detected the expression level of chemokines in DCs by real-time-qPCR and found that the DCs treated with the supernatant of Hep3B/LV-IL37 cells expressed elevated levels of the mRNA encoding CXCL10 compared with DCs treated with the supernatant of Hep3B/LV-NC, DMEM with recombinant IL-37, or DMEM alone (Figure 3C). The secretion of CXCL10 was determined by ELISA and the same results were obtained (Figure 3D). The levels of IL-2, IL-6, IL-10, IL-12, IL-12p70, TNF-α, IFN-α and IFN-γ secreted by DCs were measured by ELISA. Compared with other conditions, the DCs treated with the supernatant of Hep3B/LV-IL37 cells secreted more IL-2, IL-12, IL-12p70, IFN-α and IFN-γ. (Figure 3D). However, there was no obvious difference between the other conditions. Interestingly, although recombinant IL-37 down-regulated the secretion of IL-6 and TNF-α in DCs, no significant differences were found between DCs treated with the supernatant of Hep3B/LV-IL37 and Hep3B/LV-NC cells. And there was no obvious difference in IL-10 secretion among all groups (Figure 3E). These results suggested that IL-37 may indirectly enhance the ability of DCs to induce anti-tumor immune response.
IL-37 indirectly strengthens the cytotoxicity of CTLs induced by DCs
As the most potent type of major professional APC, the anti-tumor effect of DCs mainly depends on the action of CTLs, especially CD8+T cells.8 Moreover, IFN-γ secreted by CTLs is the most important protective agent against tumor growth.29 To investigate whether IL-37 could enhance the anti-tumor effects of CTLs by stimulating DCs to secrete cytokines, we co-cultured T lymphocytes with DCs treated with the supernatant of Hep3B/LV-IL37 cells, the supernatant of Hep3B/LV-NC cells, DMEM with recombinant IL-37, or DMEM alone. After 7 days, we tested the proliferative ability of T lymphocytes through flow cytometry and determined that it was not influenced by the presence of IL-37 (Figure 4A). The level of IFN-γ secreted by T lymphocytes was also examined through flow cytometry. DCs treated with the supernatant of Hep3B/LV-IL37 cells enhanced IFN-γ secretion by T lymphocytes more than DCs treated with the supernatant of Hep3B/LV-NC cells, DMEM with recombinant IL-37, or DMEM alone (Figure 4B). More importantly, the proportion of IFN-γ+ T cells and IFN-γ+ CD8+T cells had increased significantly (Figure 4C and D). Then, we tested the cytotoxicity of T lymphocytes on Hep3B cells. We found that DCs treated with the supernatant of Hep3B/LV-IL37 cells enhanced the cytotoxicity of T lymphocytes more than DCs treated with the supernatant of Hep3B/LV-NC cells, DMEM with recombinant IL-37, or DMEM alone (Figure 4E). Consequently, IL-37 indirectly strengthens the cytotoxicity of CTLs induced by DCs.
Overexpression IL-37 in HCC cells inhibits tumor growth and increases the recruitment of CD11c+ DCs in vivo
To investigate the correlation between the anti-tumor function of IL-37 and the infiltration of DCs in tumor tissues in vivo. We used the lentivirus mentioned untimely to establish stable Hepa 1–6 cell lines (Hepa 1–6/LV-IL37 and Hepa 1–6/LV-NC cells). Western blotting and ELISA were performed to determine the transfection efficiencies. Hepa 1–6/LV-IL37 cells (397.60±20.67 pg/mL) released a much higher level IL-37 than Hepa 1–6/LV-NC cells (81.55±5.06 pg/mL) (Figure 5A and B). The effect of IL-37 on Hepa 1–6 cell viability in vitro was confirmed. We found that there was no significant difference in the growth of Hepa 1–6/LV-IL37 and Hepa 1–6/LV-NC cells (Figure 5C). Then, a C57BL/6 mouse model by subcutaneous injection of Hepa 1–6/LV-IL37 and Hepa 1–6/LV-NC cells was established. The result showed that although there is no significant difference in the occurrence time of the tumor, the growth rate of the tumor was obviously slowed down, the tumor volume and weight were reduced in mice injected with Hepa 1–6/LV-IL37 cells (9.39±2.96 mm3, 0.05±0.01 g, n=6) compared with Hepa 1–6/LV-NC cells (43.53±17.37 mm3, 0.17±0.03 g, n=6) (Figure 5D–F). Finally, tumor blocks were surgically removed and collected to evaluate the expression of IL-37 and the infiltration of CD11c+ DCs, CD4+T cells and CD8+T cells via immunohistochemical analysis. Similar to the above findings, the level of CD11c+ DCs infiltration was significantly higher in the Hepa 1–6/LV-IL37 group (21.5±1.12 cells/HPF, n=6) than in the Hepa 1–6/LV-NC group (5.83±0.60 cells/HPF, n=6), while there was no significant difference for the numbers of intratumoral infiltrating CD4+T cells and CD8+T cells (Figure 5G–J). These results suggested that IL-37 it might promote the recruitment and activation of DCs in the tumor microenvironment to inhibit tumor progression.
The interplay of a tumor with its microenvironment is crucial to HCC pathogenesis. As an essential modulator of the processes of tumor invasion and metastasis, the interaction between tumor cells and tumor matrix has been extensively studied. The HCC microenvironment consists of hepatoma cells, stromal cells, growth factors, inflammatory cytokines, and extracellular matrix proteins.30 Tumor-associated neutrophils, tumor-associated macrophages, and DCs, as immune effector and regulatory cells in the tumor microenvironment, are significant factors in the occurrence and development of malignant tumors.31,32 which can be polarized after exposure to the tumor matrix to have either tumor-promoting or anti-tumor effects. These cells are conducive to the proliferation and invasion of cancer cells, angiogenesis of tumor tissues, formation of immunosuppressive microenvironment and pre-metastatic niches in distal tissues.
DCs are essential in adaptive immune responses and anti-tumor responses.33 As a critical participant in tumor immunity and tumor vaccine development, DCs have been widely concerned.34 Accumulating evidence suggests that the tumor microenvironment prevents DCs maturation or polarizes DCs differentiation; then, the ability of DCs to take up and deliver antigen to lymphocyte cells is reduced or even disappeared.35 However, the function of DCs in the tumor microenvironment can be regulated to restore their role in the anti-tumor immune response. IL-12 can reverse the damage of allogeneic T cell stimulation by DCs.36 Expression of co-stimulatory molecules and the ability of inducing tumor-specific cytotoxic cells were enhanced of DCs overexpressing IL-12.37 IL-24 exerts anti-tumor effects by significantly increasing the expression of co-stimulatory molecules and MHC molecules on the surface of DCs and improving the antigen-presenting ability of DCs.38 Cao et al found that DCs transfected with IL-18 can induce stronger therapeutic anti-tumor immunity.39 Moreover, it has been reported that IL-37 can mediate the combined anti-tumor effects of IL-12 and IL-18.14 These studies indicate that some cytokines can exert an anti-tumor effect by regulating DCs function.
IL-37, a cytokine of the IL-1 family. Studies of many types of tumors showed that IL-37 has a tumor suppressive effect, colon cancer, cervical cancer, and prostate cancer included.15,17,18 Gao et al confirmed that IL-37 could significantly inhibit the growth of sarcoma; moreover, the anti-tumor immunoreaction of IL-37 is dependent on T cells and B cells, but not NK cells.14 Previously, we demonstrated that IL-37 also showed a tumor suppressive effect in HCC. HCC cells overexpressing IL-37 might recruit NK cells into tumor stroma and induce an enhanced anti-tumor response.19
In this study, the expression level of IL-37 was positively associated with the degree of CD1a+ DCs infiltration in 155 HCC patients, and the IL-37highDChigh patients were found to have the best prognoses. The results of chemotaxis assays and mouse experiments were consistent with tissue specimen from patient with HCC. In a previous study, Cai et al also found that the infiltration of lymphocytes and DCs in tumor tissues of HCC, as an independent prognostic factor, was closely related to postoperative prognosis.40 In addition, we found that IL-37 has no direct effect on the migration of DCs. It stimulated chemokine release by tumor cells to recruit DCs into tumor tissue indirectly. Interestingly, we found that recombinant IL-37 decreases the expression of CD40 on DCs and down-regulated the secretion of IL-6 and TNF-α in DCs. While HCC cells expressing IL-37 increase the expression of CD86, CD40 and MHC class II on DCs and up-regulated the secretion of IL-2, IL-12, IL-12p70, IFN-α and IFN-γ. This is not entirely consistent with previous studies. Luo et al suggested that IL-37 treatment decreases the expression of the co-stimulating molecules on DCs and down-regulates the expression of the cytokines IL-1, IL-6 and TNF-α at mRNA and protein levels; in addition, IL-37 treatment reduces the CXCR1 expression and migration ability of DCs.41 It may be due to the fact that the tumor microenvironment is inconsistent with the acute inflammatory environment, and IL-37 could indirectly regulate DC function in other ways. We also found that IL-37 could enhance the ability of DCs to induce the anti-tumor effects of CTLs by stimulating HCC cells. In mouse model, the level of CD11c+ DCs infiltration was significantly higher in the Hepa 1–6/LV-IL37 group than in the Hepa 1–6/LV-NC group, while there was no significant difference for the numbers of intratumoral infiltrating CD4+T cells and CD8+T cells. All the above results indicate that IL-37 may be a potent activator for the maturation of DCs in HCC. IL-37 could induce DCs to secrete cytokines and then enhance the anti-tumor effects of T lymphocytes by stimulating HCC cells. However, the potential molecular mechanisms of IL-37 regulating chemokines and the function of DCs still need to be further explored.
In summary, our study demonstrated that IL-37 expression was positively correlated with the degree of DCs infiltration in primary HCC tumors; moreover, both high expression of IL-37 and high infiltration by CD1a+ DCs were associated with better prognosis of patients with HCC. An increase of IL-37 expression in HCC cells intensifies their ability to recruit DCs into tumor tissues. IL-37 subsequently promote maturation of DCs and induce secretion of cytokines to augment the anti-tumor effects of CTLs by stimulating HCC cells. Thus, the positive regulation of IL-37 on DC-mediated anti-tumor immune responses may contribute to develop more effective immunotherapies for HCC.
This work was supported by grants from the National Key Research and Development Program of China (No. 2018YFC1313400), the National Natural Science Foundation of China (No.81402560; 81572865; 81472387), Guangdong Esophageal Cancer Institute Science and Technology Program (No. Q201802) and the Guangdong Province Science and Technology Plan Project (No. 2017A020215029; 2014A020212584; 2013B021800063).
All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
The authors declare that they have no competing interests in this work.
1. Laursen L. A preventable cancer. Nature. 2014;516(7529):S2–S3. doi:10.1038/516S2a
2. Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20(30):10223–10237. doi:10.3748/wjg.v20.i30.10223
3. Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma. 2017;4:81–92. doi:10.2147/JHC.S107370
4. Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma. 2017;4:93–103. doi:10.2147/JHC.S106529
5. Lu LC, Hsu CH, Hsu C, Cheng AL. Tumor heterogeneity in hepatocellular carcinoma: facing the challenges. Liver Cancer. 2016;5(2):128–138. doi:10.1159/000367754
6. Hansen M, Andersen MH. The role of dendritic cells in cancer. Semin Immunopathol. 2017;39(3):307–316. doi:10.1007/s00281-016-0592-y
7. Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol. 2018;200(2):443–449. doi:10.4049/jimmunol.1701024
8. Harimoto H, Shimizu M, Nakagawa Y, et al. Inactivation of tumor-specific CD8(+) CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol. 2013;91(9):545–555. doi:10.1038/icb.2013.38
9. Wu SD, Ma YS, Fang Y, Liu LL, Fu D, Shen XZ. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev. 2012;38(3):218–225. doi:10.1016/j.ctrv.2011.06.010
10. Han Y, Chen Z, Yang Y, et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology. 2014;59(2):567–579. doi:10.1002/hep.26694
11. Kakumu S, Ito S, Ishikawa T, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol. 2000;15(4):431–436.
12. Chen S, Akbar SM, Tanimoto K, et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett. 2000;148(1):49–57.
13. Wu B, Meng K, Ji Q, et al. Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol. 2014;176(3):438–451. doi:10.1111/cei.12284
14. Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto A. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol. 2003;170(1):107–113. doi:10.4049/jimmunol.170.1.107
15. Ge G, Wang A, Yang J, et al. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer. J Exp Clin Cancer Res. 2016;35:13. doi:10.1186/s13046-016-0444-6
16. Yan X, Zhao J, Zhang R. Interleukin-37 mediates the antitumor activity in colon cancer through beta-catenin suppression. Oncotarget. 2017;8(30):49064–49075. doi:10.18632/oncotarget.17093
17. Wang S, An W, Yao Y, et al. Interleukin 37 expression inhibits STAT3 to suppress the proliferation and invasion of human cervical cancer cells. J Cancer. 2015;6(10):962–969. doi:10.7150/jca.12266
18. Wang WQ, Zhao D, Zhou YS, et al. Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer. Acta Pharmacol Sin. 2015;36(4):528–534. doi:10.1038/aps.2015.3
19. Zhao JJ, Pan QZ, Pan K, et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Sci Rep. 2014;4:5177. doi:10.1038/srep05177
20. He S, Wang L, Wu Y, Li D, Zhang Y. CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo. J Exp Clin Cancer Res. 2010;29:37. doi:10.1186/1756-9966-29-17
21. Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology. 2012;1(9):1661–1663. doi:10.4161/onci.22033
22. Kalinski P. Dendritic cells in immunotherapy of established cancer: roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs. 2009;10(6):526–535.
23. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1(4):311–316. doi:10.1038/79758
24. Berk E, Kalinski P. Lymphocyte-polarized DC1s: effective inducers of tumor-specific CTLs. Oncoimmunology. 2012;1(8):1443–1444. doi:10.4161/onci.21295
25. de Jong EC, Smits HH, Kapsenberg ML. Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol. 2005;26(3):289–307. doi:10.1007/s00281-004-0167-1
26. Salcedo R, Hixon JA, Stauffer JK, et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol. 2009;182(7):4328–4338. doi:10.4049/jimmunol.0800471
27. Medrano RFV, Hunger A, Mendonca SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget. 2017;8(41):71249–71284. doi:10.18632/oncotarget.19531
28. Ma Y, Shurin GV, Gutkin DW, Shurin MR. Tumor associated regulatory dendritic cells. Semin Cancer Biol. 2012;22(4):298–306. doi:10.1016/j.semcancer.2012.02.010
29. McCormack R, de Armas L, Shiratsuchi M, Podack ER. Killing machines: three pore-forming proteins of the immune system. Immunol Res. 2013;57(1–3):268–278. doi:10.1007/s12026-013-8469-9
30. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011;21(1):35–43. doi:10.1016/j.semcancer.2010.10.007
31. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16(3):183–194. doi:10.1016/j.ccr.2009.06.017
32. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol. 2015;194(7):2985–2991. doi:10.4049/jimmunol.1403134
33. Strioga M, Schijns V, Powell DJ
34. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419–426. doi:10.1038/nature06175
35. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711. doi:10.1146/annurev.immunol.21.120601.141040
36. Ormandy LA, Farber A, Cantz T, et al. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol. 2006;12(20):3275–3282. doi:10.3748/wjg.v12.i20.3275
37. Vogt A, Sievers E, Lukacs-Kornek V, et al. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int. 2014;34(3):447–461. doi:10.1111/liv.12284
38. Yu X, Xia W, Zhang T, et al. Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells. Int J Hematol. 2010;92(2):276–282. doi:10.1007/s12185-010-0654-1
39. Cao DY, Yang JY, Dou KF, Ma LY, Teng ZH. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Hum Immunol. 2007;68(5):334–341. doi:10.1016/j.humimm.2007.01.008
40. Cai XY, Gao Q, Qiu SJ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132(5):293–301. doi:10.1007/s00432-006-0075-y
41. Luo Y, Cai X, Liu S, et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A. 2014;111(42):15178–15183. doi:10.1073/pnas.1416714111
Table S1 Primers for real-time quantitative polymerase chain reaction analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]